Literature DB >> 23724866

Combination checkpoint blockade--taking melanoma immunotherapy to the next level.

James L Riley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23724866     DOI： 10.1056/NEJMe1305484

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  42 in total

1.  Immunotherapy at large: the road to personalized cancer vaccines.

Authors:  Robert H Vonderheide; Katherine L Nathanson
Journal:  Nat Med       Date:  2013-09       Impact factor: 53.440

2.  CAR T cells for acute myeloid leukemia: the LeY of the land.

Authors:  Malcolm K Brenner
Journal:  Mol Ther       Date:  2013-11       Impact factor: 11.454

3.  Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.

Authors:  Satish Gopal; Monita R Patel; Chad J Achenbach; Elizabeth L Yanik; Stephen R Cole; Sonia Napravnik; Greer A Burkholder; W Christopher Mathews; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron
Journal:  Clin Infect Dis       Date:  2014-04-21       Impact factor: 9.079

4.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

5.  Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-06-03       Impact factor: 8.110

6.  Strength of PD-1 signaling differentially affects T-cell effector functions.

Authors:  Fang Wei; Shi Zhong; Zhengyu Ma; Hong Kong; Andrew Medvec; Rafi Ahmed; Gordon J Freeman; Michelle Krogsgaard; James L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

7.  T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

Authors:  Daniel E Speiser; Daniel T Utzschneider; Susanne G Oberle; Christian Münz; Pedro Romero; Dietmar Zehn
Journal:  Nat Rev Immunol       Date:  2014-09-26       Impact factor: 53.106

Review 8.  Mitigating the toxic effects of anticancer immunotherapy.

Authors:  Tara C Gangadhar; Robert H Vonderheide
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

9.  The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

Authors:  Stuart J Gallagher; Branka Mijatov; Dilini Gunatilake; Jessamy C Tiffen; Kavitha Gowrishankar; Lei Jin; Gulietta M Pupo; Carleen Cullinane; Rab K Prinjha; Nicholas Smithers; Grant A McArthur; Helen Rizos; Peter Hersey
Journal:  J Invest Dermatol       Date:  2014-06-06       Impact factor: 8.551

10.  Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Authors:  Andrew J Rech; Robert H Vonderheide
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.